Education
About Us
Working with TipRanks
Follow Us
Tvardi Therapeutics (DE:69C)
FRANKFURT:69C
RESEARCH TOOLSreports
69C Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
69C Stock 12 Month Forecast
Average Price Target
€36.20
▲(55.37% Upside)
| Highest Price Target€37.54 | Average Price Target€36.20 | Lowest Price Target€34.86 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Best Analysts Covering Tvardi Therapeutics
Which Analyst Should I Follow If I Want to Buy DE:69C and Sell After:
1 Month
xxx
Success Rate
1/1 ratings generated profit
Average Return
+27.10%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +27.10% per trade.
3 Months
xxx
Success Rate
1/1 ratings generated profit
Average Return
+27.10%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +27.10% per trade.
1 Year
Success Rate
1/1 ratings generated profit
Average Return
+6.40%
initiated a buy rating 16 days ago
Copying Christopher Liu's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of +6.40% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
Average Return
+27.10%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +27.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
69C Analyst Recommendation Trends
Rating
Jun 24
Aug 24
Dec 24
Apr 25
May 25
Strong Buy
7
5
0
2
2
Buy
0
0
0
0
1
Hold
5
6
7
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
11
7
5
5
Each month's total comprises the sum of three months' worth of ratings.
69C Financial Forecast
69C Stock Forecast FAQ
What is DE:69C’s average 12-month price target, according to analysts?
Based on analyst ratings, Tvardi Therapeutics’s 12-month average price target is 36.20.
What is DE:69C’s upside potential, based on the analysts’ average price target?
Tvardi Therapeutics has 55.37% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Tvardi Therapeutics a Buy, Sell or Hold?
Tvardi Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Tvardi Therapeutics’s share price target?
The average share price target for Tvardi Therapeutics is 36.20. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €37.54 ,and the lowest forecast is €34.86. The average share price target represents 55.37% Increase from the current price of €23.3.
The highest analyst share price target is €37.54 ,and the lowest forecast is €34.86. The average share price target represents 55.37% Increase from the current price of €23.3.
What do analysts say about Tvardi Therapeutics?
Tvardi Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of Tvardi Therapeutics?
To buy shares of DE:69C, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.